Physician profile
Michael Mendelson
NPI 1376545061
$1,488.07
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $24.30 · 2022: $562 · 2023: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493 · Education: $22.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.57 |
| Education | $22.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $266.39 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $249.48 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $187.87 | 2019-2022 | |
| Abbvie INC. | $156.05 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $86.30 | 2022-2023 | Dificid |
| Allergan, INC. | $67.37 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.44 | 2019-2023 | Xifaxan |
| Daiichi Sankyo INC. | $55.49 | 2022-2023 | Injectafer |
| Intercept Pharmaceuticals, INC. | $44.06 | 2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $43.89 | 2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.89 | 2023 | Cyltezo |
| Pfizer INC. | $41.18 | 2019 | |
| Evoke Pharma, INC. | $37.75 | 2022 | |
| Redhill Biopharma INC. | $34.32 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Nestle Healthcare Nutrition INC. | $30.82 | 2022-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $22.87 | 2023 | Yuflyma |
| Ferring Pharmaceuticals INC. | $19.32 | 2022 | |
| Ardelyx, INC. | $16.49 | 2023 | Ibsrela |
| Vivus LLC | $15.99 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.10 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mendelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.